Cutiss Ag on Muck Rack

Cutiss Ag

As seen in: EClinicalMedicine, KXAN-TV (Austin, TX), WKRG-TV (Mobile, AL), KHON-TV (Honolulu, HI), WHTM-TV (Harrisburg, PA), WCMH-TV (Columbus, OH), KLFY-TV (Lafayette, LA), WRBL-TV (Columbus, GA), WSAV-TV (Savannah, GA), WLNS-TV (Lansing, MI) and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cutiss

Contact Cutiss, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in adolescent and adult burn patients: 1-year results of a prospective, randomized, controlled, multicenter phase IIB clinical trial

|
By Martin Meuli, Cutiss Ag, Esther Middelkoop, Amsterdam UMC
| EClinicalMedicine Verified
Keywords Cultured autologous dermo-epidermal skin graft Burns Donor site Scar Bioengineering Regenerative medicine Clinical trial Evidence before this study The use of cultured epithelial autografts (CEA), that is epidermal layers only, for burn treatment has been known since the 1980s. However, over the past four decades, numerous—mostly retrospective—studies have reported inconsistent graft take rates and poor functional and aesthetical long-term clinical outcomes.
Open in Who Shared Issue with article?

CUTISS closes CHF 56M Series C round and signs agreement with leading EU burn center

|
By Cutiss Ag
| WANE-TV (Fort Wayne, IN) Verified
CUTISS closes CHF 56M Series C round and signs agreement with leading EU burn center News provided by Sep 10, 2025, 2:00 AM ET Funding to support Phase 3 trial of denovoSkin™ and preparation for its commercialization, to advance the automation platform for tissue bioengineering, and to enable the market launch of VitiCell®. Agreement with Rode Kruis Ziekenhuis establishes basis for a future CUTISS production center in The Netherlands.
Open in Who Shared View Duplicates (113) Issue with article?
See all 19 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified